Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of lymphoma called CD20-positive diffuse large B-cell lymphoma (DLBCL), confirmed by a tissue test
• People whose lymphoma is only present in the central nervous system — meaning the brain, spinal cord, eyes, or the lining around the brain and spinal cord
• People where tests including scans and a bone marrow test have confirmed the lymphoma has not spread to any other part of the body
• People who have not previously received chemotherapy or radiation therapy (a small, short course of a steroid called dexamethasone at low doses for fewer than 5 days may be acceptable — confirm with trial site)
• People aged 18 to 75 years (inclusive)
• People with a general health and activity level rated between 0 and 3 on a standard medical scale (this covers people who are fully active through to people who are capable of limited self-care — confirm with trial site)
• People who have at least one measurable area of lymphoma that is 1.0 cm or larger, as seen on a specialised brain scan (enhanced MRI)
• People expected to live for at least 3 months, in the opinion of the treating doctor
• People who are willing and able to read and sign a consent form
• People who are able to attend follow-up visits on schedule and communicate well with the research team throughout the trial
• Women who could become pregnant must agree to use highly effective contraception during treatment and for 6 months after the last dose; men who are sexually active must also agree to use highly effective contraception during treatment and for 6 months after the last dose

Who may not be able to join:

• People whose lymphoma has spread to parts of the body outside the central nervous system
• People who have previously received chemotherapy, radiation therapy, or a stem cell transplant
• People who have or have had another cancer that currently requires active treatment
• People who have a chronic or currently active infection requiring ongoing antibiotic, antifungal, or antiviral treatment (infections with a virus called EBV may be an exception — confirm with trial site)
• People with uncontrolled heart or blood vessel disease, bleeding disorders, clotting disorders, or connective tissue diseases
• People with other uncontrolled health conditions that the research team considers unsuitable for participation
• People whose blood test results at the start of the trial fall outside acceptable ranges — including low counts of white blood cells, neutrophils (a type of immune cell), platelets, or haemoglobin, or abnormally high levels of certain liver or kidney markers (unless these are caused by the lymphoma itself — confirm with trial site)
• People with active hepatitis B infection, active hepatitis C infection, HIV, or other inherited or acquired immune deficiency conditions (people with certain hepatitis B markers may still be considered if specific virus level tests come back below a set threshold — confirm with trial site)
• People who are pregnant or currently breastfeeding
• People with a history of drug use or substance abuse
• People with a mental illness or any condition that may make it difficult to fully follow the study requirements
• People with a known allergy to the trial drug or any of its ingredients
• People who are unable to swallow capsules, or who have a condition that seriously affects how their digestive system absorbs or processes food and medication, such as removal of the stomach or small intestine, or a complete bowel blockage
• People who are unable to have an enhanced MRI scan
• People considered unsuitable for the trial for any other reason, at the discretion of the research team

Important: Always verify eligibility with the trial site directly before applying.